Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;117:863-865
doi: 10.1161/CIRCULATIONAHA.107.756346
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shimokawa, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shimokawa, H.
Related Collections
Right arrow Cell biology/structural biology
Right arrow Other Vascular biology

(Circulation. 2008;117:863-865.)
© 2008 American Heart Association, Inc.


Editorial

Bone Marrow–Derived Matrix Metalloproteinase-14

A Novel Target for Plaque Stability

Hiroaki Shimokawa, MD, PhD

From the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Correspondence to Hiroaki Shimokawa, MD, PhD, Professor and Chairman, Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1–1 Seiryo-machi, Aoba-ku, Sendai 980–8574, Japan. E-mail shimo@cardio.med.tohoku.ac.jp


Key Words: Editorials • atherosclerosis • bone marrow • matrix metalloproteinases


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

Our understanding of the role of bone marrow (BM)–derived cells in the pathogenesis of vascular disease has been evolving rapidly. It is generally accepted that circulating monocytes, the precursors of macrophages, migrate to the vascular wall and differentiate into lipid-laden macrophages in the process of atherogenesis.1 BM-derived cells with smooth muscle cell (SMC)–like phenotype also participate in the pathogenesis of vascular disease.2,3 Circulating endothelial progenitor cells migrate to the site of vascular injury and participate in arterial repair and angiogenesis.4 A recent study revealed an important role of T cells in hypertension and vascular dysfunction.5 The vasculature possesses several agonist/receptor systems that affect recruitment and differentiation of BM-derived cells, including granulocyte-macrophage colony stimulating factor,6 stromal cell–derived factor-1,7 and erythropoietin.8,9 These accumulating findings have established the role of BM-derived cells (eg, macrophages, lymphocytes, and vascular progenitors) in the pathogenesis of cardiovascular disease. Activated SMCs, macrophages, and immune cells are abundant in vulnerable atheroma that is often covered with a thin and collagen-poor fibrous cap and/or aggregating platelets (the Figure). Activated SMCs and macrophages are major cell components that produce matrix metalloproteinases (MMPs) in the atherosclerosis plaque. MMPs degrade extracellular matrix and play crucial roles in the pathogenesis of plaque disruption and subsequent thrombosis.10 Among these MMPs, MMP-14 is a membrane-bound MMP that activates pro–MMP-2 and is closely associated with migration of monocyte-derived cells.11 However, the role of MMP-14 in atherosclerosis in vivo remains poorly defined.


Figure Removed (Available Only in the Full Text)
View larger version (43K):



 
Figure. Role of MMP-14 in BM-derived cells in the pathogenesis of plaque vulnerability. BM-derived cells . . . [Full Text of this Article]